User profiles for Mariel J. Liebeskind
 | Mariel J. LiebeskindSUNY Upstate Medical University Verified email at upstate.edu Cited by 1446 |
[PDF][PDF] Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …
vaccines and have received emergency use authorization as therapeutics. However, viral …
Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study
…, K Huang, B Kinnett, MJ Liebeskind… - Annals of internal …, 2021 - acpjournals.org
Background: Patients with chronic inflammatory disease (CID) treated with immunosuppressive
medications have increased risk for severe COVID-19. Although mRNA-based SARS-…
medications have increased risk for severe COVID-19. Although mRNA-based SARS-…
[HTML][HTML] Defining the risk of SARS-CoV-2 variants on immune protection
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants jeopardizes the protective antiviral immunity induced after infection or …
variants jeopardizes the protective antiviral immunity induced after infection or …
[HTML][HTML] Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2
…, A Haile, K Huang, B Kinnett, MJ Liebeskind… - MedRxiv, 2021 - ncbi.nlm.nih.gov
Background: Individuals with chronic inflammatory diseases (CID) are frequently treated
with immunosuppressive medications that can increase their risk of severe COVID-19. While …
with immunosuppressive medications that can increase their risk of severe COVID-19. While …
Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Although neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of
most COVID-19 vaccines and being developed as therapeutics, escape mutations could …
most COVID-19 vaccines and being developed as therapeutics, escape mutations could …
A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants
…, R Van den Doel, MJ Liebeskind… - Proceedings of the …, 2021 - National Acad Sciences
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has resulted in over 100 million infections and millions of deaths. Effective vaccines remain …
has resulted in over 100 million infections and millions of deaths. Effective vaccines remain …
[HTML][HTML] Pooled image-base screening of mitochondria with microraft isolation distinguishes pathogenic mitofusin 2 mutations
…, CL Kremitzki, JE Waligorski, MJ Liebeskind… - Communications …, 2022 - nature.com
Most human genetic variation is classified as variants of uncertain significance. While
advances in genome editing have allowed innovation in pooled screening platforms, many …
advances in genome editing have allowed innovation in pooled screening platforms, many …
[HTML][HTML] A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination
SE Greene, Y Huang, W Kim, MJ Liebeskind… - Journal of clinical …, 2023 - Elsevier
Objective Lateral flow assays (LFA) are sensitive for detecting antibodies to SARS-CoV-2
proteins within weeks after infection. This study tested samples from immunocompetent adults, …
proteins within weeks after infection. This study tested samples from immunocompetent adults, …
Mitochondrial Phenotypes Distinguish Pathogenic MFN2 Mutations by Pooled Functional Genomics Screen
…, CL Kremitzki, JE Waligorski, MJ Liebeskind… - bioRxiv, 2021 - biorxiv.org
Most human genetic variation is classified as VUS - variants of uncertain significance. While
advances in genome editing have allowed innovation in pooled screening platforms, many …
advances in genome editing have allowed innovation in pooled screening platforms, many …
Low-Cost Manually Assembled Open Source Reader for Isothermal Pathogen Detection from Saliva using RT-LAMP: SARS-CoV-2 Use Case
…, JE Waligorski, CL Kremitzki, MJ Liebeskind… - medRxiv, 2020 - medrxiv.org
Distributed “Point-of-Care” or “at-Home” testing is an important component for a complete
suite of testing solutions. This manuscript describes the construction and operation of a …
suite of testing solutions. This manuscript describes the construction and operation of a …